Trial Profile
A Pilot Study to Assess the Safety and Efficacy of Sarilumab in Halting Progression of Morphea
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 13 Sep 2021
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Circumscribed scleroderma
- Focus Therapeutic Use
- 31 Aug 2021 Planned End Date changed from 5 Nov 2021 to 30 Jun 2021.
- 31 Aug 2021 Planned primary completion date changed from 5 Nov 2021 to 30 Jun 2021.
- 31 Aug 2021 Status changed from recruiting to withdrawn prior to enrolment.